InvestSMART

LTR Pharma Ltd (ASX: LTP) - Announcements

Current share price for LTP : $0.488 0.003 (0.51%)+

ASX company news and announcements for LTR Pharma Ltd (LTP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All LTR Pharma Ltd (LTP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than LTR Pharma Ltd (LTP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for LTR Pharma Ltd (LTP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$89 LTR Expands Men's Health Portfolio with KYZATREX Pilot 1 Sep 2026 8:15AM $0.505 $0.488 fallen by 3.47%
$89 FY26 Results Announcement 28 Aug 2026 7:48AM $0.480 $0.488 risen by 1.56%
$89 Appendix 4G and Corporate Governance Statement 28 Aug 2026 7:48AM $0.480 $0.488 risen by 1.56%
$89 Appendix 4E and Annual Report to Shareholders 28 Aug 2026 7:48AM $0.480 $0.488 risen by 1.56%
$89 SPONTAN Real-World Study Reports 93% Response 11 Aug 2026 8:32AM $0.470 $0.488 risen by 3.72%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jul 2026 9:01AM $0.510 $0.488 fallen by 4.41%
$89 LTR Executes U.S. Commercial Agreement with Strive 20 Jul 2026 8:55AM $0.510 $0.488 fallen by 4.41%
$89 LTR Executes Definitive U.S. Commercial Agreement with Shed 17 Jul 2026 8:48AM $0.495 $0.488 fallen by 1.52%
$89 Notification regarding unquoted securities - LTP 10 Jul 2026 4:28PM $0.520 $0.488 fallen by 6.25%
$89 OROFLOW Clinical Study Receives Ethics Approval 24 Jun 2026 8:22AM $0.565 $0.488 fallen by 13.72%
$89 Response to ASX Aware Letter 15 Jun 2026 2:16PM $0.505 $0.488 fallen by 3.47%
$89 LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS 11 Jun 2026 8:38AM $0.425 $0.488 risen by 14.71%
$89 LTR Secures First U.S. Commercial Agreement for ROXUS 9 Jun 2026 8:35AM $0.465 $0.488 risen by 4.84%
$89 Investor Presentation 1 May 2026 9:19AM $0.405 $0.488 risen by 20.37%
$89 SPONTAN Phase II data show rapid onset, support FDA pathway 1 May 2026 9:18AM $0.405 $0.488 risen by 20.37%
$89 Trading Halt 29 Apr 2026 8:29AM $0.405 $0.488 risen by 20.37%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2026 8:52AM $0.430 $0.488 risen by 13.37%
$89 Investor Presentation 11 Mar 2026 8:40AM $0.460 $0.488 risen by 5.98%
$89 SPONTAN Phase II Clinical Study Completes Recruitment 5 Mar 2026 8:31AM $0.430 $0.488 risen by 13.37%
$89 Appendix 4D and Half Yearly Report 26 Feb 2026 8:12AM $0.490 $0.488 fallen by 0.51%
$89 Application for quotation of securities - LTP 10 Feb 2026 12:20PM $0.535 $0.488 fallen by 8.88%
$89 SPONTAN Shows Positive Outcomes in Younger Men with ED 2 Feb 2026 8:46AM $0.545 $0.488 fallen by 10.55%
$89 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:27AM $0.585 $0.488 fallen by 16.67%
$89 First Patients Dosed in SPONTAN Phase II Clinical Study 22 Jan 2026 8:52AM $0.570 $0.488 fallen by 14.47%
$89 Application for quotation of securities - LTP 21 Jan 2026 3:35PM $0.550 $0.488 fallen by 11.36%

1 - 25 of 144 results

Page 1 of 6

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.